{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:55:26Z","timestamp":1784901326431,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41391-020-0248-9","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T15:05:11Z","timestamp":1594220711000},"page":"622-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The deleterious association between proton pump inhibitors and prostate cancer-specific mortality \u2013 a population-based cohort study"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2138","authenticated-orcid":false,"given":"Hanan","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan K.","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-6905","authenticated-orcid":false,"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miran","family":"Kenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-4026","authenticated-orcid":false,"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2173-5028","authenticated-orcid":false,"given":"Thenappan","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Saarela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir M. H.","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"248_CR1","unstructured":"CCSsACoCS. Canadian Cancer Statistics 2018. 2018. http:\/\/www.cancer.ca\/Canadian-Cancer-Statistics-2018-EN."},{"key":"248_CR2","unstructured":"CoAC S. Key Statistics for Prostate Cancer. 2019. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html."},{"key":"248_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","volume":"179","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, et al. Association of treatment with 5alpha-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179:812\u20139.","journal-title":"JAMA Intern Med"},{"key":"248_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/jnci\/djt170","volume":"105","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst. 2013;105:1123\u201331.","journal-title":"J Natl Cancer Inst"},{"key":"248_CR5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl J Med. 2012;367:1792\u2013802.","journal-title":"N. Engl J Med"},{"key":"248_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2019.02.028","volume":"449","author":"I Gesmundo","year":"2019","unstructured":"Gesmundo I, Di Blasio L, Banfi D, Villanova T, Fanciulli A, Favaro E, et al. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1\/2, PI3K\/Akt, GSK-3beta signaling and inhibition of cellular prostatic acid phosphatase. Cancer Lett. 2019;449:252\u201362.","journal-title":"Cancer Lett."},{"key":"248_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0016-5085(00)70135-1","volume":"118","author":"EC Klinkenberg-Knol","year":"2000","unstructured":"Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661\u20139.","journal-title":"Gastroenterology."},{"key":"248_CR8","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","volume":"7","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.","journal-title":"BMJ Open"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","volume":"53","author":"N Brusselaers","year":"2018","unstructured":"Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172\u20137.","journal-title":"Cancer Epidemiol"},{"key":"248_CR10","doi-asserted-by":"crossref","unstructured":"Tran KT, McMenamin UC, Proton pump inhibitor histamine-2 receptor antagon use risk liver cancer two population-based studies. 2018;48:55\u201364.","DOI":"10.1111\/apt.14796"},{"key":"248_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/pds.4702","volume":"28","author":"OO Halfdanarson","year":"2019","unstructured":"Halfdanarson OO, Fall K, Ogmundsdottir MH, Lund SH, Steingrimsson E, Ogmundsdottir HM, et al. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study. Pharmacoepidemiology drug Saf. 2019;28:471\u20138.","journal-title":"Pharmacoepidemiology drug Saf"},{"key":"248_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.canlet.2016.04.015","volume":"376","author":"A Canitano","year":"2016","unstructured":"Canitano A, Iessi E, Spugnini EP, Federici C, Fais S. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett. 2016;376:278\u201383.","journal-title":"Cancer Lett."},{"key":"248_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28\u201335.","journal-title":"Gut."},{"key":"248_CR14","doi-asserted-by":"publisher","first-page":"l1580","DOI":"10.1136\/bmj.l1580","volume":"365","author":"Y Xie","year":"2019","unstructured":"Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.","journal-title":"BMJ."},{"key":"248_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4265-1","volume":"18","author":"LC Soriano","year":"2018","unstructured":"Soriano LC, Soriano-Gabarr\u00f3 M, Garc\u00eda Rodr\u00edguez LA. Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network. BMC Cancer. 2018;18:402.","journal-title":"BMC Cancer."},{"key":"248_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canep.2016.12.006","volume":"46","author":"MD Kearns","year":"2017","unstructured":"Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol. 2017;46:80\u20134.","journal-title":"Cancer Epidemiol"},{"key":"248_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41419-018-0642-6","volume":"8","author":"Y Cao","year":"2018","unstructured":"Cao Y, Chen M, Tang D, Yan H, Ding X, Zhou F, et al. The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses. Cell Death Dis. 2018;9:604.","journal-title":"Cell Death Dis"},{"key":"248_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/bjc.2015.17","volume":"112","author":"Q Tan","year":"2015","unstructured":"Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J cancer. 2015;112:832\u201340.","journal-title":"Br J cancer"},{"key":"248_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1634\/theoncologist.2018-0621","volume":"24","author":"AR Hansen","year":"2019","unstructured":"Hansen AR, Tannock IF, Templeton A, Chen E, Evans A, Knox J, et al. Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Oncologist. 2019;24:1188\u201394.","journal-title":"Oncologist"},{"key":"248_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573\u20137.","journal-title":"Ann Intern Med"},{"key":"248_CR21","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12:e1001885.","journal-title":"PLoS Med."},{"key":"248_CR22","unstructured":"Institute of Clinical Evaluative Sciences Homepage. 2019. http:\/\/www.ices.on.ca."},{"key":"248_CR23","unstructured":"The Johns Hopkins ACG (R) System version 10.0."},{"key":"248_CR24","doi-asserted-by":"publisher","first-page":"298.e19","DOI":"10.1016\/j.urolonc.2019.01.030","volume":"37","author":"RK Sayyid","year":"2019","unstructured":"Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, et al. Population-based outcomes of men with a single negative prostate biopsy: importance of continued follow-up among older patients. Urologic Oncol. 2019;37:298.e19\u2013.e27.","journal-title":"Urologic Oncol."},{"key":"248_CR25","unstructured":"The Top 300 of 2019. 2019. www.clincalc.com."},{"key":"248_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","volume":"14","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697\u2013710.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"248_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","volume":"153","author":"MF Vaezi","year":"2017","unstructured":"Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017;153:35\u201348.","journal-title":"Gastroenterology"},{"key":"248_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2131\/jts.37.969","volume":"37","author":"H Hayashi","year":"2012","unstructured":"Hayashi H, Taniai E, Morita R, Hayashi M, Nakamura D, Wakita A, et al. Enhanced liver tumor promotion but not liver initiation activity in rats subjected to combined administration of omeprazole and beta-naphthoflavone. J toxicological Sci. 2012;37:969\u201385.","journal-title":"J toxicological Sci"},{"key":"248_CR29","doi-asserted-by":"publisher","first-page":"70332","DOI":"10.18632\/oncotarget.19696","volume":"8","author":"L Huang","year":"2017","unstructured":"Huang L, Qi DJ, He W, Xu AM. Omeprazole promotes carcinogenesis of fore-stomach in mice with co-stimulation of nitrosamine. Oncotarget. 2017;8:70332\u201344.","journal-title":"Oncotarget."},{"key":"248_CR30","doi-asserted-by":"publisher","first-page":"155932581880328","DOI":"10.1177\/1559325818803283","volume":"16","author":"YC Peng","year":"2018","unstructured":"Peng YC, Lin CL, Hsu WY, Lu IT, Yeh HZ, Chang CS, et al. Proton Pump inhibitor use is associated with risk of pancreatic cancer: a nested case-control study. Dose Response. 2018;16:1559325818803283.","journal-title":"Dose Response"},{"key":"248_CR31","doi-asserted-by":"publisher","first-page":"e0189114","DOI":"10.1371\/journal.pone.0189114","volume":"12","author":"IC Hwang","year":"2017","unstructured":"Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: a Korean nationwide prospective cohort study. PloS ONE. 2017;12:e0189114.","journal-title":"PloS ONE"},{"key":"248_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41391-018-0046-9","volume":"21","author":"KV Giridhar","year":"2018","unstructured":"Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, et al. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:431\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"248_CR33","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/annonc\/mdx348","volume":"28","author":"DI Quinn","year":"2017","unstructured":"Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol: Off J Eur Soc Med Oncol. 2017;28:2658\u201369.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"248_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","volume":"14","author":"P Spanogiannopoulos","year":"2016","unstructured":"Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14:273\u201387.","journal-title":"Nat Rev Microbiol"},{"key":"248_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41391-018-0061-x","volume":"21","author":"KS Sfanos","year":"2018","unstructured":"Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21:539\u201348.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"248_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41391-018-0041-1","volume":"21","author":"CM Porter","year":"2018","unstructured":"Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:345\u201354.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"248_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.juro.2017.08.001","volume":"199","author":"E Shrestha","year":"2018","unstructured":"Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199:161\u201371.","journal-title":"J Urol"},{"key":"248_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/19490976.2017.1284732","volume":"8","author":"F Imhann","year":"2017","unstructured":"Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351\u20138.","journal-title":"Gut Microbes."},{"key":"248_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/pds.1454","volume":"16","author":"MU Yood","year":"2007","unstructured":"Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16:961\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0248-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:35:04Z","timestamp":1684618504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-0248-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-0248-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}